Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
97.31
+1.37 (1.43%)
Mar 9, 2026, 3:38 PM EDT - Market open
Incyte Employees
Incyte had 2,844 employees as of December 31, 2025. The number of employees increased by 227 or 8.67% compared to the previous year.
Employees
2,844
Change (1Y)
227
Growth (1Y)
8.67%
Revenue / Employee
$1,807,750
Profits / Employee
$452,409
Market Cap
19.37B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2,844 | 227 | 8.67% |
| Dec 31, 2024 | 2,617 | 93 | 3.68% |
| Dec 31, 2023 | 2,524 | 200 | 8.61% |
| Dec 31, 2022 | 2,324 | 230 | 10.98% |
| Dec 31, 2021 | 2,094 | 321 | 18.10% |
| Dec 31, 2020 | 1,773 | 317 | 21.77% |
| Dec 31, 2019 | 1,456 | 89 | 6.51% |
| Dec 31, 2018 | 1,367 | 159 | 13.16% |
| Dec 31, 2017 | 1,208 | 228 | 23.27% |
| Dec 31, 2016 | 980 | 288 | 41.62% |
| Dec 31, 2015 | 692 | 104 | 17.69% |
| Dec 31, 2014 | 588 | 107 | 22.25% |
| Dec 31, 2013 | 481 | 68 | 16.46% |
| Dec 31, 2012 | 413 | 45 | 12.23% |
| Dec 31, 2011 | 368 | 121 | 48.99% |
| Dec 31, 2010 | 247 | 26 | 11.76% |
| Dec 31, 2009 | 221 | 9 | 4.25% |
| Dec 31, 2008 | 212 | 16 | 8.16% |
| Dec 31, 2007 | 196 | 10 | 5.38% |
| Dec 31, 2006 | 186 | 9 | 5.08% |
| Dec 31, 2005 | 177 | -9 | -4.84% |
| Dec 31, 2004 | 186 | -268 | -59.03% |
| Dec 31, 2003 | 454 | -37 | -7.54% |
| Dec 31, 2002 | 491 | -94 | -16.07% |
| Dec 31, 2001 | 585 | -737 | -55.75% |
| Dec 31, 2000 | 1,322 | 214 | 19.31% |
| Dec 31, 1999 | 1,108 | 241 | 27.80% |
| Dec 31, 1998 | 867 | 191 | 28.25% |
| Dec 31, 1997 | 676 | 218 | 47.60% |
| Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 6,772 |
| Moderna | 4,700 |
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 2,973 |
| Insmed | 1,664 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Revolution Medicines | 883 |
INCY News
- 2 days ago - Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - Business Wire
- 6 days ago - Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 10 days ago - Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata - PRNewsWire
- 18 days ago - Incyte Remains Undervalued As Opzelura And Niktimvo Scale - Seeking Alpha
- 20 days ago - Incyte to Present at Upcoming Investor Conferences - Business Wire
- 24 days ago - Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells - Seeking Alpha
- 26 days ago - Incyte: Why The Market Is Overreacting To A Guidance 'Miss' - Seeking Alpha
- 26 days ago - Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript - Seeking Alpha